Successful Completion of Sixth Dose Escalation | 19-Sep-2023 | 07:00 | RNS |
Notice of Results | 06-Sep-2023 | 07:00 | RNS |
Issue of Equity and Total Voting Rights | 21-Jul-2023 | 15:00 | RNS |
Result of Annual General Meeting | 28-Jun-2023 | 11:00 | RNS |
Annual General Meeting and Shareholder Event | 28-Jun-2023 | 07:00 | RNS |
Completion of Fifth Dose Escalation in AVA6000 | 21-Jun-2023 | 07:00 | RNS |
Director Appointment | 19-Jun-2023 | 07:01 | RNS |
Statement regarding market speculation | 19-Jun-2023 | 07:00 | RNS |
AGM and Shareholder Event Detailed Agenda | 08-Jun-2023 | 07:00 | RNS |
Second Milestone in AffyXell Joint Venture | 05-Jun-2023 | 07:00 | RNS |
Posting of Annual Report and Notice of AGM | 02-Jun-2023 | 07:00 | RNS |
Avacta acquires Coris Bioconcept | 01-Jun-2023 | 07:00 | RNS |
Block Listing Six Monthly Return | 27-Apr-2023 | 07:00 | RNS |
First Patient Dosed in the US in AVA6000 Phase 1 | 27-Apr-2023 | 07:00 | RNS |
Preliminary Results | 25-Apr-2023 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 43.50p |
Change Today | -0.75p |
% Change | -1.69 % |
52 Week High | 159.60 |
52 Week Low | 43.00 |
Volume | 1,361,347 |
Shares Issued | 359.04m |
Market Cap | £156.18m |
RiskGrade | 461 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 2 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 1 |
Total | 3 |
No dividends found |
Time | Volume / Share Price |
16:35 | 100,000 @ 43.21p |
16:27 | 2,000 @ 43.57p |
16:23 | 10,000 @ 43.48p |
16:23 | 11,489 @ 43.47p |
16:22 | 937 @ 43.20p |
CFO | Tony Peter Gardiner |
CEO | Christina Coughlin |
You are here: research